Cyclophosphamide 200mg powder for solution for injection vials
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide.
Genetic variations that may affect drug response
2 known genetic variations may influence how your body responds to Cyclophosphamide 200mg powder for solution for injection vials.Genes involved: CYP3A4, CYP2B6
These are known genetic variations. They don't mean the medicine won't work for you — speak to your doctor or a pharmacogenomics specialist for personalised advice. Source: DrugBank (CC BY-NC 4.0).
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Cyclophosphamide
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Cyclophosphamide
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(10)
Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (TA308)
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)
Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)
Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (TA311)
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (TA825)
Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia (TA29)
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)
Idelalisib for treating chronic lymphocytic leukaemia (TA359)
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)
Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 19 · Randomised trials: 28 · 1975–2026
Showing the 50 most relevant studies, sorted by most relevant.
B. Eichhorst, A. Fink, J. Bahlo, et al.
The Lancet. Oncology, 2016
Donald P. Tashkin, Michael D. Roth, Philip J. Clements, et al.
The Lancet Respiratory Medicine, 2016
- Cyclophosphamide
- Immunosuppressive Agents
- Lung
R. B. Jones, T. Hiemstra, J. Ballarin, et al.
Annals of the Rheumatic Diseases, 2019
N. D. Niemeijer, G. Alblas, L. T. Hulsteijn, et al.
Clinical Endocrinology, 2014
T. Maher, Veronica A Tudor, P. Saunders, et al.
The Lancet. Respiratory medicine, 2022
F. Scolari, Elisa Delbarba, D. Santoro, et al.
Journal of the American Society of Nephrology : JASN, 2021
N. Gagelmann, A. Bacigalupo, A. Rambaldi, et al.
JAMA oncology, 2019
M. Hallek, K. Fischer, G. Fingerle-Rowson, et al.
Lancet, 2010
Frédéric Houssiau, Carlos Vasconcelos, David D’Cruz, et al.
Arthritis & Rheumatism, 2002
- Azathioprine
- Cyclophosphamide
- Immunosuppressive Agents
M. Piccart
JNCI Journal of the National Cancer Institute, 2000
- Alopecia
- Antineoplastic Combined Chemotherapy Protocols
- Cisplatin
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
3-12 hours
Mechanism
Alkylating agents work by three different mechanisms: 1) attachment of alkyl gro…
Food interactions
2 warnings
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
3-12 hours
Protein binding
20%
Volume of distribution
30-50 L
Metabolism
75%
Elimination
10-20%
Clearance
7.6 L/kg
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[L50141]
Cyclophosphamide oral capsules are additionally indicated for the treatment of minimal change nephrotic syndrome in pediatric patients who fail to adequately respond to (or are unable to tolerate) adrenocorticosteroid therapy.
[L50557]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1427 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Cyclophosphamide appears to induce its own metabolism which results in an overall increase in clearance, increased formation of 4-hydroxyl metabolites, and shortened t1/2 values following repeated administration.
Proteins and enzymes this drug interacts with in the body
Response to specific ligands is species-specific. Activated by naturally occurring steroids, such as pregnenolone and progesterone. Binds to a response element in the promoters of the CYP3A4 and ABCB1/MDR1 genes
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC L01AA01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Cyclophosphamide
Additional database identifiers
Drugs Product Database (DPD)
5927
ChemSpider
2804
BindingDB
50237604
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7968
GenAtlas
NR1I2
GeneCards
NR1I2
GenBank Gene Database
AF061056
GenBank Protein Database
3511138
Guide to Pharmacology
606
UniProt Accession
NR1I2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2623
GenAtlas
CYP2C9
GeneCards
CYP2C9
GenBank Gene Database
AY341248
Guide to Pharmacology
1326
UniProt Accession
CP2C9_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2615
GeneCards
CYP2B6
GenBank Gene Database
M29874
GenBank Protein Database
181296
Guide to Pharmacology
1324
UniProt Accession
CP2B6_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2621
GeneCards
CYP2C19
GenBank Gene Database
M61854
GenBank Protein Database
181344
Guide to Pharmacology
1328
UniProt Accession
CP2CJ_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2610
GenAtlas
CYP2A6
GeneCards
CYP2A6
GenBank Gene Database
X13897
Guide to Pharmacology
1321
UniProt Accession
CP2A6_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2620
GeneCards
CYP2C18
GenBank Gene Database
M61853
Guide to Pharmacology
1327
UniProt Accession
CP2CI_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2638
GenAtlas
CYP3A5
GeneCards
CYP3A5
GenBank Gene Database
J04813
GenBank Protein Database
181346
Guide to Pharmacology
1338
UniProt Accession
CP3A5_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2622
GenAtlas
CYP2C8
GeneCards
CYP2C8
GenBank Gene Database
M17397
Guide to Pharmacology
1325
UniProt Accession
CP2C8_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q408524), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.